Asieris(SH:688176) Zhong Guo Jing Ji Wang·2025-10-15 06:26Core Viewpoint - The financial performance of Yahui Pharmaceutical (688176.SH) in the first half of 2025 shows significant revenue growth but continues to report net losses, indicating ongoing challenges in profitability despite increased sales [1][3]. Financial Performance - The company achieved operating revenue of 130.24 million yuan in the first half of 2025, representing a year-on-year increase of 61.80% compared to 80.49 million yuan in the same period last year [1][3]. - The net profit attributable to shareholders was -162.21 million yuan, an improvement from -183.99 million yuan in the previous year [1][3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -177.15 million yuan, compared to -196.91 million yuan in the same period last year [1][3]. - The net cash flow from operating activities was -194.27 million yuan, an improvement from -242.84 million yuan year-on-year [1][3]. Historical Performance - From 2018 to 2024, the net profit attributable to shareholders has shown a consistent trend of losses, with figures ranging from -59.93 million yuan in 2018 to -384 million yuan in 2024 [3]. - The net profit after deducting non-recurring gains and losses also reflects a similar trend, with losses increasing from -64.05 million yuan in 2018 to -409 million yuan in 2024 [3]. Company Background - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an initial issuance of 110 million shares at a price of 22.98 yuan per share [4]. - The stock price has been in a state of decline since its debut, with the highest price recorded at 20.00 yuan on the first trading day [4]. - The total funds raised from the initial public offering amounted to 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs [4].